Table 4.
Variables | OR (95% CI) | P value | ||||||
Promoter (likelihood to recommend ≥9) | ||||||||
|
Intercept | 1.47 (0.56-3.84) | .43 | |||||
|
Patient–provider communication | |||||||
|
|
1-2 follow-up visits | 2.06 (1.33-3.20) | <.001 | ||||
|
|
3-4 follow-up visits | 2.17 (1.27-3.70) | .01 | ||||
|
|
≥5 follow-up visits | 3.32 (1.42-7.79) | .01 | ||||
|
Pain and function changes | |||||||
|
|
Function MCIDb | 1.85 (1.17-2.93) | .01 | ||||
|
|
Large pain MCID | 2.84 (1.68-4.78) | <.001 | ||||
|
Controls | |||||||
|
|
Female | 2.23 (1.48-3.34) | <.001 | ||||
|
|
Baseline function | 1.09 (1.01-1.17) | .03 | ||||
|
|
Baseline pain | 0.85 (0.22-0.95) | .004 |
aA total of 32 imputed values (782 original).
bMCID: minimal clinically important difference.